|Bid||0.0000 x 2200|
|Ask||0.0000 x 1200|
|Day's Range||4.2100 - 4.4185|
|52 Week Range||2.1300 - 7.6200|
|Beta (5Y Monthly)||2.33|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Atyr Pharma (LIFE) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Atyr Pharma (LIFE) delivered earnings and revenue surprises of 238.89% and 83.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?